A Potential Major Breakthrough & NASDAQ Up-Listing Has Investors Taking Notice Of GTBP
This year’s $12 billion acquisition of Kite Pharma, Inc. by big-pharma giant, Gilead Sciences has biotech investors hungry. Therefore, many have started to search for “the next Kite” opportunity. What if we told you that some of the “top brass” in the biotechnology sector have made a move to join a company that, right now, is flying under the radar of larger investment firms?
Merck & Co Buys Into KalVista For $760 Million For Diabetic Eye Disease
Merck & Co, just partnered with Kalvista for its plasma Kallikrien inhibitors. Merck is set to pay $37 million upfront for an option to purchase KalVista’s program in diabetic macular edema, a buildup of fluid in the eye can result in loss of sight, and has also agreed to give up to $715 million in milestones also including royalties if it leads to a commercial product. It’s also paying $9 million for a 9.9% stake in the biotech company.
GET ALERTS FASTER!
TEXT “BIOTECH” TO 474747 NOW!
BIOTECHSTOCKS,.com is owned by MIDAM VENTURES LLC., a Florida Corporation that has been compensated $800,000.00 by a GT Biopharma Inc. for a period beginning August 1, 2017 and ending Nov. 1, 2017 to publicly disseminate information about (GTBP). We own zero shares.